{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Recombinant Growth Factor[C530]" in comments (approximate match)
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT01107756: Phase 4 Interventional Completed Neoplasms (no Otherwise Specified)
(2010)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Class (Stereo):
CHEMICAL (ABSOLUTE)
Semparatide (previously known as RS-66271) was developed as an analog of parathyroid hormone-related protein (PTHrP) with shortening the time for fracture healing. Experiments on animals have shown that this compound was an effective therapy for preventing impaired bone healing caused by prednisone. Clinical trials with postmenopausal osteoporotic women have revealed that semparatide cause sustained increases in the spine. However, further, development appears to have been discontinued by Roche.
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
